Mitteilungsseiten des Deutschen Zentralkomitees zur Bekämpfung der Tuberkulose (DZK)

• Literatur

• 1 WHO, rapid communication: key chances to treatment of drug-resistant tuberculosis. Geneva: World Health Organization (WHO/CDS/TB/2019.26); 2019
• 2 WHO, WHO consolidated guidelines on drug-resistant tuberculosis treatment, W. h. organisation, Editor. Geneva: 2019 Licence: CC BY-NC-SA 3.0 IGO
• 3 Campbell JR. et al. Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials. Lancet Infect Dis 2019;